UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 37

Sortiert nach

Efficacy and safety evaluation of Fanhdi®, a plasma‐derived factor VIII/ von Willebrand factor concentrate, in Von Willebrand's disease patients undergoing surgery or invasive procedures: A prospective clinical study

Haemophilia : the official journal of the World Federation of Hemophilia, 2022-01, Vol.28 (1), p.e23-e27

2022

Volltextzugriff (PDF)

Predictive factors of immune tolerance treatment response in severe haemophilia A patients with inhibitors: A real‐world report from a single centre, mixed retrospective‐prospective long‐term study

Haemophilia : the official journal of the World Federation of Hemophilia, 2019-03, Vol.25 (2), p.e97-e100

2019

Volltextzugriff (PDF)

Prophylactic treatment in hemophilic patients with inhibitors

Blood coagulation & fibrinolysis, 2019-09, Vol.30 (1S Suppl 1), p.S14

Haya, Saturnino

2019

Volltextzugriff (PDF)

Cross‐sectional comparative study of pharmacokinetics and efficacy between sucrose‐formulated recombinant factor VIII (Kogenate®) and BAY 81‐8973 (Kovaltry®) in patients with severe or moderate haemophilia A in prophylaxis

Haemophilia : the official journal of the World Federation of Hemophilia, 2019-05, Vol.25 (3), p.e215-e218

2019

Volltextzugriff (PDF)

Emicizumab-induced photosensitivity

TH open : companion journal to thrombosis and haemostasis, 2022-07, Vol.6 (3), p.e154-e155

2022

Volltextzugriff (PDF)

Allogeneic hematopoietic cell transplantation in an adult patient with Glanzmann thrombasthenia

Clinical case reports, 2017-11, Vol.5 (11), p.1887-1890

2017

Volltextzugriff (PDF)

Severe and moderate hemophilia A: identification of 38 new genetic alterations

Haematologica (Roma), 2008-07, Vol.93 (7), p.1091-1094

2008

Volltextzugriff (PDF)

National Survey on the Use of Mobile Applications in Patients with Hemophilia and Other Coagulopathies

Blood, 2022-11, Vol.140 (Supplement 1), p.11308-11309

2022

Volltextzugriff (PDF)

Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A

Blood, 2013-09, Vol.122 (11), p.1954-1962

2013

Volltextzugriff (PDF)

Benefits of Ehl Factor VIII Replacement Therapy in Hemophilia: Observations on Coverage, Physical Activity and Phisiotherapy

Blood, 2019-11, Vol.134 (Supplement_1), p.2455-2455

2019

Volltextzugriff (PDF)

Clinical benefits of a Bayesian model for plasma-derived factor VIII/VWF after one year of pharmacokinetic-guided prophylaxis in severe/moderate hemophilia A patients

Thrombosis research, 2021-09, Vol.205, p.99-105

2021

Volltextzugriff (PDF)

Significant linkage and non‐linkage of type 1 von Willebrand disease to the von Willebrand factor gene

British journal of haematology, 2001-12, Vol.115 (3), p.692-700

2001

Volltextzugriff (PDF)

Clinical and molecular characterization by next generation sequencing of Spanish patients affected by congenital deficiencies of fibrinogen

Thrombosis research, 2019-08, Vol.180, p.115-117

2019

Volltextzugriff (PDF)

Factor XIII deficiency in two Spanish families with a novel variant in gene F13A1 detected by next-generation sequencing; symptoms and clinical management

Journal of thrombosis and thrombolysis, 2020-10, Vol.50 (3), p.686-688

2020

Volltextzugriff (PDF)

Individualized Prophylactic Treatment with Recombinant Factor VIII in Severe or Moderate Haemophilia a Patients. Association Between Pharmacokinetic Parameters and Clinical Variables

Blood, 2016-12, Vol.128 (22), p.3802-3802

2016

Volltextzugriff (PDF)

Management of acquired hemophilia A: results from the Spanish registry

Blood advances, 2021-10, Vol.5 (19), p.3821-3829

2021

Volltextzugriff (PDF)

C0400 Relation between thrombotic symptoms and fibrin generation kinetics in patients with dysfibrinogenemia

Thrombosis research, 2012-10, Vol.130, p.S199-S199

2012

Volltextzugriff (PDF)

Large deletion in the Factor VIII gene (F8) involving segmental duplications in int22h shows no haematological phenotype in female carriers, but may be embryonic lethal in males

British journal of haematology, 2012-07, Vol.158 (1), p.138-140

2012

Volltextzugriff (PDF)

Preliminary Observations from the European Study on Orthopedic Status (ESOS) in Hemophilia Patients with Inhibitors

Blood, 2006-11, Vol.108 (11), p.1037-1037

2006

Volltextzugriff (PDF)

Novel missense mutation c.2685G>C (p.Q895H) in gene associated with very low levels of VWF mRNA

Annals of hematology, 2008-08, Vol.88 (3), p.245-247

2008

Volltextzugriff (PDF)

Identification of deletion carriers in hemophilia B: quantitative real-time polymerase chain reaction or multiple ligation probe amplification

Translational research : the journal of laboratory and clinical medicine, 2009-03, Vol.153 (3), p.114-117

2009

Volltextzugriff (PDF)

Novel missense mutation c.2685G>C (p.Q895H) in VWF gene associated with very low levels of VWF mRNA

Annals of hematology, 2009-03, Vol.88 (3), p.245-247

2009

Volltextzugriff (PDF)

Von Willebrand's disease : a novel mutation, P18241 and the incidence of R1205H defect among families with dominant quantitative von Willebrand factor deficiency

Haematologica (Roma), 2006, Vol.91 (8), p.1130-1133

2006

Volltextzugriff (PDF)

Von Willebrand's disease: a novel mutation, P1824H and the incidence of R1205H defect among families with dominant quantitative von Willebrand factor deficiency

Haematologica (Roma), 2006-08, Vol.91 (8), p.1130-1133

2006

Volltextzugriff (PDF)

1 – 25 von 37

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(34)
Mit Volltextzugriff
(33)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(23)
Science & Technology
(23)
Hematology
(21)
Humans
(19)
Female
(13)
Male
(12)
Biological And Medical Sciences
(9)
Medical Sciences
(9)
Hematologic And Hematopoietic Diseases
(8)
Pedigree
(7)
Platelet Diseases And Coagulopathies
(7)
Von Willebrand Factor - Genetics
(7)
Adult
(6)
Von Willebrand Disease
(6)
Von Willebrand Diseases - Genetics
(6)
Phenotype
(5)
Adolescent
(4)
Child
(4)
Factor Viii - Therapeutic Use
(4)
Heterozygote
(4)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Efficacy and safety evaluation of Fanhdi®, a plasma‐derived factor VIII/ von Willebrand factor concentrate, in Von Willebrand's disease patients undergoing surgery or invasive procedures: A prospective clinical study

Predictive factors of immune tolerance treatment response in severe haemophilia A patients with inhibitors: A real‐world report from a single centre, mixed retrospective‐prospective long‐term study

Prophylactic treatment in hemophilic patients with inhibitors

Cross‐sectional comparative study of pharmacokinetics and efficacy between sucrose‐formulated recombinant factor VIII (Kogenate®) and BAY 81‐8973 (Kovaltry®) in patients with severe or moderate haemophilia A in prophylaxis

Emicizumab-induced photosensitivity

Allogeneic hematopoietic cell transplantation in an adult patient with Glanzmann thrombasthenia

Severe and moderate hemophilia A: identification of 38 new genetic alterations

National Survey on the Use of Mobile Applications in Patients with Hemophilia and Other Coagulopathies

Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A

Benefits of Ehl Factor VIII Replacement Therapy in Hemophilia: Observations on Coverage, Physical Activity and Phisiotherapy

Clinical benefits of a Bayesian model for plasma-derived factor VIII/VWF after one year of pharmacokinetic-guided prophylaxis in severe/moderate hemophilia A patients

Significant linkage and non‐linkage of type 1 von Willebrand disease to the von Willebrand factor gene

Clinical and molecular characterization by next generation sequencing of Spanish patients affected by congenital deficiencies of fibrinogen

Cross-Sectional Comparative Study of PK-Guided Switch between Standard Half-Life and Extended Half-Life Factor VIII Products

Factor XIII deficiency in two Spanish families with a novel variant in gene F13A1 detected by next-generation sequencing; symptoms and clinical management

Individualized Prophylactic Treatment with Recombinant Factor VIII in Severe or Moderate Haemophilia a Patients. Association Between Pharmacokinetic Parameters and Clinical Variables

Management of acquired hemophilia A: results from the Spanish registry

C0400 Relation between thrombotic symptoms and fibrin generation kinetics in patients with dysfibrinogenemia

Large deletion in the Factor VIII gene (F8) involving segmental duplications in int22h shows no haematological phenotype in female carriers, but may be embryonic lethal in males

Preliminary Observations from the European Study on Orthopedic Status (ESOS) in Hemophilia Patients with Inhibitors

Novel missense mutation c.2685G>C (p.Q895H) in gene associated with very low levels of VWF mRNA

Identification of deletion carriers in hemophilia B: quantitative real-time polymerase chain reaction or multiple ligation probe amplification

Novel missense mutation c.2685G>C (p.Q895H) in VWF gene associated with very low levels of VWF mRNA

Von Willebrand's disease : a novel mutation, P18241 and the incidence of R1205H defect among families with dominant quantitative von Willebrand factor deficiency

Von Willebrand's disease: a novel mutation, P1824H and the incidence of R1205H defect among families with dominant quantitative von Willebrand factor deficiency

Suchergebnisse filtern